XM does not provide services to residents of the United States of America.
S
S

Sonova

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Sonova Holding Opens New Facility in Mexico

BRIEF-Sonova Holding AG - Opens New Facility in Mexico Feb 7 (Reuters) - SONOVA HOLDING AG SOON.S : SONOVA HOLDING AG - SONOVA TODAY ANNOUNCES OPENING OF A NEW FACILITY THAT WILL HOUSE TWO SEPARATE OPERATION CENTERS FOR ITS HEARING INSTRUMENTS AND COCHLEAR IMPLANTS BUSINESSES SONOVA HOLDING AG - FACILITY IS LOCATED IN AN INDUSTRIAL AREA IN MEXICALI
S

EPS to determine 2024 winners and losers in European medtech -MS

BUZZ-EPS to determine 2024 winners and losers in European medtech -MS ** Morgan Stanley expects earnings per share (EPS) to indicate 2024 winners and losers in European medical technology, saying EPS revisions should produce above-average price moves after some recovery in 2023 ** It notes 2023 already saw some earnings re-basing due to a combinati
B
S
A
F

Growth in focus as macro questions linger on EU Consumer MedTech - Bernstein

BUZZ-Growth in focus as macro questions linger on EU Consumer MedTech - Bernstein ** Bernstein says the key question regarding European consumer medical technologies sector in 2024 is the trajectory of underlying market growth across many of the sub-markets ** The broker sees concerns on dental and hearing aid stocks as overdone relative to the act
S
S
A

'Convalescence is over': Jefferies sees upbeat 2024 for European MedTech

BUZZ-'Convalescence is over': Jefferies sees upbeat 2024 for European MedTech ** Jefferies initiates coverage of eleven European medical technology firms, with seven "buy" ratings, seeing a better 2024 after a downbeat market performance over the past two years ** It says hopes for normalized inflation and stabilizing rates make MedTech attractive
C
E
P
S
S
S
A

BNP raises Sonova to 'outperform' on growing momentum

BUZZ-BNP raises Sonova to 'outperform' on growing momentum ** BNP Paribas raises Sonova SOON.S to "overperform" from "underperform" as it sees downgrade cycle for the Swiss hearing aid maker's EPS coming to an end ** The broker cites improving momentum, rising market share in wholesale, prospects of recovery in Consumer Hearing and Cochlear Implant as possible drivers for strong growth acceleration ** BNP notes Sonova's shares are trading at an all-time low of 20x P/E despite its momentum ahead
C
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.